Skip to main content

Pacritinib Dosage

Medically reviewed by Last updated on Aug 26, 2022.

Applies to the following strengths: 100 mg

Usual Adult Dose for Myelofibrosis

200 mg orally 2 times a day

Use: Treatment of patients with intermediate or high-risk primary or secondary (post-polycythemia vera OR post-essential thrombocythemia) myelofibrosis (MF) with a platelet count less than 50 times 10(9)/L (50 x 10(9)/L)

Renal Dose Adjustments

Estimated GFR (eGFR) 30 mL/min and over: Data not available
eGFR less than 30 mL/min: Not recommended.

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate and severe liver dysfunction (Child-Pugh B and C): Not recommended.

Dose Adjustments

Concomitant kinase inhibitor use: Prior to starting this drug, patients receiving treatment with other kinase inhibitor(s) should taper or discontinue the other kinase inhibitor(s) per manufacturer recommendations.

Planned surgical procedures/other interventions: This drug should be discontinued 7 days before the procedure/intervention, and then should be restarted only after hemostasis is reassured.



QT prolongation:




Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.


eGFR less than 15 and hemodialysis: Not recommended.
Peritoneal dialysis: Data not available

Other Comments

Administration advice:

Storage requirements:



Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.